Boston Scientific reported weaker-than-expected Q3 2026 earnings and lowered its sales and earnings guidance for the third straight quarter, citing operational impacts and remediation costs from a major cybersecurity incident and challenges in key product segments. Following this announcement, the company's stock dropped nearly 6%. Pomerantz LLP has launched an investigation into whether Boston Scientific and its executives engaged in securities fraud or other unlawful practices, potentially leading to a class action lawsuit. Investors affected by the situation are encouraged to contact the law firm for more information.
Boston Scientific's stock is currently trading at USD 43.99 on Pluang, down 2.53% in the last day. Most investors on the platform are selling, with 97% of order activity as sell orders. These figures are as of Nov 12, 2026, 22:51 WIB.
